IRCT201102175855N1 IRCT 2011-04-11 Ahvaz Jondishapour University of Medical Sciences Riboflavin and multiple sclerosis A study on nutritional status of riboflavin and the effect of riboflavin supplementation on disability and quality of life scores in patients with multiple sclerosis 2010-10-18 anticipated 30 Complete https://irct.ir/trial/6325 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Single, Purpose: Treatment, Other design features: We will obtain 5 ML blood for measuring erythrocyte glutathione reductase activity coefficients in fasting. Also, intervention and control groups will obtain riboflavin supplementation (10 mg) and placebo for 24 weeks. Neither patient nor researcher don’t informed about which patient set in which group until complete study. Patients will continue their medications. Patients in two groups will complete MSQOL54 questionnaire in the first, sixth and twelfth weeks of study and physician will measured their EDSS. Also 5 ML blood will be obtained for measuring erythrocyte glutathione reductase activity coefficients in fasting in the twelfth week. The score of MSQOL54 questionnaire alternatives which be answered by patients will change to numbers between 0 to 100 and will categorize as percent. Higher score illustrates the better patient life style independent to health. 1 Multiple sclerosis. Intervention 1: one 10 mg Riboflavin capsul per day, oral, for 6 mounts. Intervention 2: placebo: lactos, one capsul per day, for 6 mounts.